Myeloma Center
Found 56 results
Author Title Type [ Year(Asc)]
Filters: Filter is   [Clear All Filters]
2015
Niesvizky R, Badros AZ, Costa LJ, Ely SA, Singhal SB, Stadtmauer EA, Haideri NA, Yacoub A, Hess G, Lentzsch S et al..  2015.  Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.. Leuk Lymphoma. 56(12):3320-8.
Krishnan U, Mark TM, Niesvizky R, Sobol I.  2015.  Pulmonary hypertension complicating multiple myeloma.. Pulm Circ. 5(3):590-7.
Vij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel DS.  2015.  Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma.. Leuk Lymphoma. 56(10):2959-61.
2014
Geyer JT, Niesvizky R, Jayabalan DS, Mathew S, Subramaniyam S, Geyer AI, Orazi A, Ely SA.  2014.  IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.. Mod Pathol. 27(3):375-81.
Palumbo A, S Rajkumar V, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC et al..  2014.  International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.. J Clin Oncol. 32(6):587-600.
Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui A-M, Gupta N, Di Bacco A, Yu J et al..  2014.  Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.. Blood. 124(7):1047-55.
Mark TM, Coleman M, Niesvizky R.  2014.  Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.. Leuk Res. 38(5):517-24.
Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, A Stewart K, Hari P, Roy V, Vescio R et al..  2014.  Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.. Lancet Oncol. 15(13):1503-12.
Mark TM, Bowman IA, Rossi AC, Shah M, Rodriguez M, Quinn R, Pearse RN, Zafar F, Pekle K, Jayabalan D et al..  2014.  Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.. Leuk Lymphoma. 55(12):2842-9.
2013
Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R.  2013.  Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety.. Leukemia. 27(8):1707-14.
Rosenbaum C, Jasielec J, Laubach J, Prada CPaba, Richardson P, Jakubowiak AJ.  2013.  Evolving strategies in the initial treatment of multiple myeloma.. Semin Oncol. 40(5):592-601.
Dimopoulos MA, Terpos E, Niesvizky R.  2013.  How lenalidomide is changing the treatment of patients with multiple myeloma.. Crit Rev Oncol Hematol. 88 Suppl 1:S23-35.
Niesvizky R.  2013.  Immunomodulatory agents changing the landscape of multiple myeloma treatment.. Crit Rev Oncol Hematol. 88 Suppl 1:S1-4.
Siegel D, Martin T, Nooka A, R Harvey D, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K et al..  2013.  Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.. Haematologica. 98(11):1753-61.
Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, van Besien K, Shore T.  2013.  A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.. Biol Blood Marrow Transplant. 19(5):831-7.
Wang M, Martin T, Bensinger W, Alsina M, Siegel DS, Kavalerchik E, Huang M, Orlowski RZ, Niesvizky R.  2013.  Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.. Blood. 122(18):3122-8.
Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, Wegener WA, Goldenberg DM.  2013.  Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.. Br J Haematol. 163(4):478-86.
Richardson PG, Mark TM, Lacy MQ.  2013.  Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.. Crit Rev Oncol Hematol. 88 Suppl 1:S36-44.
Kwon D, Niesvizky R.  2013.  Treatment of multiple myeloma with carfilzomib in patients with renal injury.. Clin Adv Hematol Oncol. 11(9):605-6.
2012
A Wernicke G, Sabbas A, Kulidzhanov F, Shamis M, Golster Y, Niesvizky R, Lane J.  2012.  A single-dose conformal delivery of radiotherapy following osteoplasty : a novel approach to treatment of osteolytic metastasis in the setting of multiple myeloma.. HSS J. 8(2):169-74.
2011
Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ, Chen-Kiang S, Sparano JA.  2011.  Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.. Cancer. 117(2):336-42.
2010
Niesvizky R, Coleman M, Mark T.  2010.  Best practices in the management of newly diagnosed multiple myeloma patients who will not undergo transplant.. Oncology (Williston Park). 24(3 Suppl 2):14-21.
Gay F, S Rajkumar V, Coleman M, Kumar S, Mark T, Dispenzieri A, Pearse R, Gertz MA, Leonard J, Lacy MQ et al..  2010.  Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.. Am J Hematol. 85(9):664-9.
2009
Mark T, Martin P, Leonard JP, Niesvizky R.  2009.  Milatuzumab: a promising new agent for the treatment of lymphoid malignancies.. Expert Opin Investig Drugs. 18(1):99-104.
Mark T, Niesvizky R, Coleman M.  2009.  Novel agents in myeloma: an exciting saga.. Cancer. 115(2):236-42.